3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
361
Precursor Cell Lymphoblastic Leukemia-Lymphoma
328
Lymphoma
297
Leukemia
254
Multiple Myeloma
246
Leukemia, Myeloid, Acute
241
Lymphoma, Non-Hodgkin
240
Lymphoma, Large B-Cell, Diffuse
238
Leukemia, Lymphocytic, Chronic, B-Cell
220
Myelodysplastic Syndromes
184
Lymphoma, Follicular
176
Hodgkin Disease
165
Lymphoma, Mantle-Cell
163
Burkitt Lymphoma
160
Lymphoma, B-Cell, Marginal Zone
117
Recurrence
115
Lymphoma, Large-Cell, Immunoblastic
95
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
82
Myeloproliferative Disorders
81
Melanoma
78
Neoplasms, Plasma Cell
77
Leukemia, Myeloid, Chronic-Phase
72
Hematologic Neoplasms
72
Leukemia, Myeloid, Accelerated Phase
71
Leukemia, Myelomonocytic, Chronic
69
Lymphoma, B-Cell
65
Dendritic Cell Sarcoma, Interdigitating
64
Triple Negative Breast Neoplasms
63
Ovarian Neoplasms
61
Congenital Abnormalities
59
Interventions
Nivolumab
5
palbociclib
2
Radiosurgery
2
Protons
2
Proton Therapy
2
Pemetrexed
2
Ipilimumab
2
Imatinib Mesylate
2
tazemetostat
1
relatlimab
1
pembrolizumab
1
nilotinib
1
camrelizumab
1
apatinib
1
Zoledronic Acid
1
Thiotepa
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Photochemotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Panobinostat
1
Melphalan
1
Mastectomy, Segmental
1
Immunoglobulin G
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Disulfides
1
Dihematoporphyrin Ether
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Chordoma
×
Cyclophosphamide
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled